Crescendo Bioscience Names Industry Leader Oscar Segurado, M.D., Ph.D., Chief Medical Officer
Published: Jun 13, 2012
SOUTH SAN FRANCISCO, Calif., June 13, 2012 (GLOBE NEWSWIRE) -- Crescendo Bioscience®, a molecular diagnostics company developing and commercializing quantitative, biology-based tests for rheumatoid arthritis (RA) and other auto-immune diseases, announced today that as part of the company's expansion, it has named Oscar Segurado, M.D., Ph.D., as Chief Medical Officer. Dr. Segurado will oversee the strategic growth and clinical development of Vectra™ DA, Crescendo Bioscience's test for measuring RA disease activity, as well as the research and development of other novel auto-immune and inflammatory tests. In addition, the company appointed David Chernoff, M.D., to the role of Senior Vice President of Medical Affairs. Dr. Chernoff will continue to build relationships and liaison with the medical community toeducate on the need for and advancement of molecular diagnostics in RA and other autoimmune diseases, and work closely with collaborators as the company grows its diagnostic portfolio.